Skip to main content
. 2023 Jan 10;13:1009484. doi: 10.3389/fimmu.2022.1009484

Figure 2.

Figure 2

Cytotoxic effects of expanded NK cells from HDs (NK-HD) and GBM patients (NK-GBM) against GBM cells, Iri-treated GBM, and Bev plus Iri-treated GBM cells. The cytotoxicity effects of NK-HD (A–D) and NK-GBM cells (E–G) against GBM cells such as U87, U118, U343, pGBM at 1:1 and 1:3 (target:effector) ratio were confirmed through the LDH assay. U87, U118, and U343: human GBM cell lines; pGBM: primary GBM cells; Bev: bevacizumab (0.5 mg/mL); Iri: irinotecan (0.15 mg/mL). All data are shown as mean ± SD. p< 0.05 (*), p< 0.001 (**), p< 0.0001 (***).